NCT06903221进行中（未招募）4 期
A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation With Bordetella Pertussis Using Controlled Human Infection
Dimitri Diavatopoulos2 个研究点 分布在 1 个国家目标入组 99 人开始时间: 2024年10月16日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 99
- 试验地点
- 2
- 主要终点
- Bordetella pertussis (Bp) colonisation rate
研究概览
简要总结
The goal of this clinical trial is to investigate the effect of booster vaccination with acellular pertussis vaccine on colonization with Bordetella pertussis using a controlled human infection model in healthy volunteers. The main questions it aims to answer are:
- Whether booster vaccination with Tdap-IPV reduces Bp colonisation after intranasal challenge with the standard Bp inoculum dose compared to the Td-IPV control group
- Compare Bp colonisatation in participants vaccinated with Tdap-IPV after intranasal challenge with the standard and a 'high' Bp inoculum dose
Research will compare Tdap-IPV vaccination - standard inoculum dose with Td-IPV vaccination - standard inoculum dose, and Tdap-IPV vaccination - standard inoculum dose with Tdap-IPV vaccination - high inoculum dose to see how Tdap-IPV vaccination and the high inoculum dose have an effect on colonisation rate.
Participants will be vaccinated with Tdap-IPV or Td-IPV and 2-4 months later challenged with the standard or 'high' inoculum. After challenge there is a follow up visit for 28 days in which they fill in a daily symptom diary and have 6 visits to the hospital.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant (male/female) is born before 1-9-2004 and < 50 years old on the day of screening
- •Participant has received all primary pertussis vaccines during childhood
- •Participant is in good health as confirmed by review of medical history and physical examination
- •Participant has adequate understanding of the procedures of the study and agrees to abide strictly thereby
- •Participant is able to answer all questions of the pre-consent questionnaire correctly
- •Participant is fully conversant in the Dutch language
- •Participant is capable and willing to give personal signed informed consent.
- •Participant is able to communicate by both mobile telephone and text messaging
- •Participant is willing and available to attend all study visits
- •Participant agrees to inform his/her general practitioner (GP) about participation in the study
- •Participant agrees to provide access to information regarding their vaccination background
- •Participant agrees to provide a treating physician access to all study-related information and data
- •Participant is able to arrive within 1h at the Radboudumc from his/her home address. The participant must have a home address and live in the Netherlands
- •Participant is able to arrive within 3h at the Radboudumc at any time between Bp inoculation until the day 28 post challenge visit
- •Participant is willing to take an antibiotic regimen after inoculation with Bp according to the study protocol
- •Participant is willing to use infection control measures during social contact during the study
- •Participant is willing to attend to the Radboudumc immediately if they become symptomatic
排除标准
- •Incapacitated subjects without decision-making capacity.
- •A confirmed diagnosis of pertussis in the last two years and/or serum IgG anti-FHA >56 IU/mL
- •History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention.
- •Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
- •Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •Individuals who are at risk of complications of a prolonged cough, such as individuals with stress urine incontinence, pelvic floor dysfunction or an inguinal hernia
- •Chronic use of i) immunosuppressive drugs (e.g. systemic steroids, steroid nasal spray or isotretinoin), ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period.
- •Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention.
- •Drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset
- •Diabetes mellitus
- •Smoking: Any smoking event in the last month, including (e-)cigarette, joint, cigar and pipe
- •Infection with Bp or any other Bordetella species at the baseline for challenge visit
- •Individuals who have a history of receiving pertussis vaccination in the last 5 years
- •Acute illness within 3 days prior to Bp inoculation (including mild upper respiratory tract infection, common cold, running nose)
- •Any antibiotic treatment within 4 weeks before inoculation
- •Receipt of any non-study vaccine within 14 days, before and after receiving the study vaccine or Bp inoculation
- •For female participants: pregnancy, lactation or intention to become pregnant during the study. Female volunteers are required to use an effective form of contraception during this study. Acceptable forms of contraception include:
- •Established use of oral, injected or implanted hormonal methods of contraception
- •Placement of an intrauterine device or intrauterine system
- •Total hysterectomy
- •Barrier methods of contraception (condom or occlusive cap with spermicide)
- •Male sterilisation if the vasectomised partner is the sole partner for the participant
- •True abstinence when this is in line with the preferred and usual lifestyle of the participant
- •Known hypersensitivity to or contra-indications (including co-medication) for use of azithromycin or macrolides, see: azitromycine (oraal) (farmacotherapeutischkompas.nl). This includes: Clinically relevant bradycardia, hypokalemia, hypocalcemia and hypomagnesemia, cardiac arrhythmia or severe heart failure, congenital or acquired QT-prolongation, use of comedication which can cause QT-prolongation or is contraindicated co-medication: for a full list see: azitromycine (oraal) (farmacotherapeutischkompas.nl) - interactions.
- •Participation in any other clinical study (unless observational) in the three months prior to the start of the study or during the study period
- •Being an employee or student of the department of Laboratory Medicine, Radboudumc
- •Any other condition or situation that would, in the opinion of the investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol
- •Individuals who have inviolable commitments within the study period during the challenge (28 days in total) to make contact with:
- •infants aged < 1 year
- •unimmunized children aged < 4 years
- •pregnant women >32 weeks who have not received pertussis vaccination at least a week prior to contact
- •chronically ill patients (e.g. asthma, COPD, heart diseases)
- •Individuals who have household contacts working with
- •infants aged < 1 year
- •pregnant women
- •The use of mouthwash during the challenge (35 days)
研究组 & 干预措施
Td-IPV - standard inoculum dose
Placebo Comparator
Participants get vaccinated with Td-IPV and will be challenged with 10E5 CFU Bordetella pertussis
干预措施: Td-IPV (Drug)
Tdap-IPV - standard inoculum dose
Experimental
Participants get vaccinated with Tdap-IPV and will be challenged with 10E5 CFU Bordetella pertussis
干预措施: Tdap-IPV (Drug)
Tdap-IPV - high inoculum dose
Experimental
Participants get vaccinated with Tdap-IPV and will be challenged with 10E6 CFU Bordetella pertussis
干预措施: Tdap-IPV (Drug)
结局指标
主要结局
Bordetella pertussis (Bp) colonisation rate
时间窗: Day 3-28 post challenge
Bp colonisation rate in Tdap-IPV and Td-IPV vaccination groups, with Bp colonisation defined as any positive Bp culture from nasal wash samples at any time point between Day 3 and Day 28 after challenge
次要结局
- Safety: solicited adverse events (AEs)(Day 0-28 post challenge)
- Safety: azithromycin treatment(Day 0-28 post challenge)
- Safety: unsolicited AEs(Day 0-28 post challenge)
- Colony forming unit (CFU) counts(Day 3-28 post challenge)
- Geometric mean concentration of Bp-specific antibodies(5 months)
研究者
Dimitri Diavatopoulos
Senior researcher
Radboud University Medical Center
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 YearsHerpes ZosterNCT04869982GlaxoSmithKline6,138
已完成
2 期
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)Meningococcal DiseaseNCT01992536Novartis Vaccines194
已完成
2 期
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19COVID-19 VaccineNCT05197153Medigen Vaccine Biologics Corp.804
已完成
1 期
Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult VolunteersPulmonary TuberculosisNCT01599897Access to Advanced Health Institute (AAHI)60
已完成
4 期
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in AdolescentsMeningococcal MeningitisNCT01424644Novartis801